<DOC>
	<DOCNO>NCT01418755</DOCNO>
	<brief_summary>Recently articular cartilage repair give much attention orthopaedic field . Cartilage regeneration capacity limit . Optimal approach seem delivery natural growth factor . Autologous platelet-rich plasma ( PRP ) contain proliferative chemoattractant growth factor . The objective present study determine PRP increase tibiofemoral cartilage regeneration improve knee function .</brief_summary>
	<brief_title>Study Platelet-rich Plasma Treating Patients With Tibiofemoral Cartilage Degeneration</brief_title>
	<detailed_description>Fifty consecutive strictly select patient , affect Grade II III chondromalacia , underwent one year treatment ( 9 injection ) autologous PRP liquid form 2,0 2,5-fold platelet concentration . Outcome measure include hte Lysholm , Tegner , IKDC , Cincinnati score . Magnetic resonance imaging use evaluate cartilage thickness degree degeneration .</detailed_description>
	<criteria>isolate Grade II Grade III nontraumatic chondromalacia accord Outerbridge grade scale Grade I ( soften ) Grade IV ( expose subchondral bone ) tibiofemoral chondromalacia ; patellofemoral chondral damage ; associate intraarticular lesion confirm arthroscopy ( meniscus , ligament , osteochondral defect ) ; associate extraarticular lesion confirm magnetic resonance imaging ( ligament , tendon , bursa ) ; low limb axial deviation confirm whole leg weightbearing radiograph ; knee trauma patient history ; body mass index ( BMI ) high 35 ; hyaluronic acid intraarticular injection 6 month prior arthroscopy last followup control ; steroid intraarticular injection 3 month prior arthroscopy last followup control ; symptomatic slow act drug osteoarthritis ( SYSADOA ) and/or nonsteroidal antiinflammatory drug ( NSAID ) administration PRP treatment ; systemic autoimmune rheumatic and/or polyarticular disease ; gout , pseudogout hyperuricaemia . Other exclusion criterion include : noninformed consent ; treat knee injury PRP therapy ; PRP injection cycle complete ; impediment fill questionnaire ; blood disease and/or immunosuppressant treatment and/or dicoumarol therapy ; immunosuppressant and/or neoplastic and/or infectious disease .</criteria>
	<gender>All</gender>
	<minimum_age>31 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Platelet-Rich Plasma</keyword>
	<keyword>Knee</keyword>
	<keyword>Tibiofemoral Chondromalacia</keyword>
	<keyword>Injection</keyword>
</DOC>